Ignite Creation Date:
2025-12-24 @ 6:36 PM
Ignite Modification Date:
2025-12-29 @ 2:29 AM
Study NCT ID:
NCT07178457
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-09-17
First Post:
2025-08-25
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance
Sponsor:
Assistance Publique - Hôpitaux de Paris
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-11-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2032-11-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2032-11-01
Completion Date Type:
ESTIMATED
First Submit Date:
2025-08-25
First Submit QC Date:
None
Study First Post Date:
2025-09-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-10
Last Update Post Date:
2025-09-17
Last Update Post Date Type:
ESTIMATED